Multi-omics Mendelian Randomization for IBS Drug Target Discovery

5,642 potential druggable protein-coding genes were analyzed for causal effects on irritable bowel syndrome risk. The analysis integrated summary statistics from a genome-wide association study of 53,400 cases and 433,201 controls with blood expression quantitative trait loci data. This dataset, authored by Huiwen Ke and last updated in May 2026, presents the results identifying candidate drug targets EP300 and P2RY14.

Use Cases

• Prioritizing genetically validated drug targets for irritable bowel syndrome based on Mendelian randomization results.
• Assessing potential on-target adverse effects for candidate genes using phenome-wide association study results.
• Predicting existing therapeutic compounds for candidate targets using molecular docking data.
• Validating causal gene-disease associations through colocalization analysis.

Strengths

• Analysis is based on a large-scale GWAS with 53,400 IBS cases and 433,201 controls.
• Systematic evaluation of 5,642 potential druggable protein-coding genes.
• Results are validated with colocalization analysis and phenome-wide association study.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Data is contained in a 92.5 KB DOCX file, suggesting limited raw data and a focus on summary results.

Provenance

Source

figshare

Collection Method

Systematic druggable genome-wide Mendelian randomization integrating GWAS and eQTL summary statistics.

Freshness

Last updated 2026-05-18 22:02:52; freshness should be verified.